ASMB Stock Forecast: Assembly Biosciences, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$22
−1.38% on the day

The 5 Wall Street analysts covering Assembly Biosciences, Inc. hold a median 12-month price target of $50 — +125.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 79 of 100 as at 21 Nov 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$454.4M
Ticker Nerd rank
79/ 100
Median analyst target
$50
Analysts covering
5
Revenue$13.4M+38.9% y/y
Operating income−$6.3M
Net income−$3.9M
Free cash flow−$15.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+5.1%
1M
+4.7%
YTD
−34.8%
1Y
−39.6%
From 52W high
−42.4%
From 52W low
+13.7%
$20
$39
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Assembly Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
79/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
96
Value
92
Growth
91
Volatility
90
Revisions
64
Momentum
53
Issuance
31
Accruals
8

Quality (96): The business earns solid, repeatable profits on what it owns.

Accruals (8): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

ASMB stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ASMB, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$30$40$50$60Jan 26Apr 26Jul 26Oct 26ASMBHigh $62Median $50Low $43

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
5
Buy
0
Hold
0
Sell
$43
Low
$50
Median
$62
High

The green dot is the last close — the median target sits +125.3% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 2 moved their price target up and 2 moved it down.

DateFirmActionRatingTarget
3 Nov 2026UBSMaintainsBuy$52 → $48
1 Sept 2026MizuhoMaintainsOutperform$53 → $45
1 Sept 2026UBSInitiatesBuy$52
18 Aug 2026HC Wainwright & Co.ReiteratesBuy$50
15 June 2026MizuhoMaintainsOutperform$40 → $45
28 May 2026GuggenheimReiteratesBuy—
4 May 2026HC Wainwright & Co.ReiteratesBuy—
6 Apr 2026GuggenheimMaintainsBuy—
26 Mar 2026HC Wainwright & Co.ReiteratesBuy—
22 Dec 2025HC Wainwright & Co.ReiteratesBuy—
20 Nov 2025MizuhoMaintainsOutperform—
14 Oct 2025HC Wainwright & Co.ReiteratesBuy—
24 Sept 2025JMP SecuritiesInitiatesMarket Outperform—
8 Sept 2025GuggenheimMaintainsBuy—
18 Aug 2025HC Wainwright & Co.AssumesBuy$50
25 Mar 2025GuggenheimInitiatesBuy—
24 Mar 2025HC Wainwright & Co.ReiteratesNeutral—
27 Dec 2024HC Wainwright & Co.ReiteratesNeutral—
24 Sept 2024HC Wainwright & Co.ReiteratesNeutral—
20 Sept 2024JefferiesUpgradeBuy$2.00 → $35

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for ASMB.

Market Radar

This page is one stock. Monday covers all of them.

ASMB appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

ASMB vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Assembly Biosciences, Inc. returned −39.6% against +6.9% for the S&P 500, dividends included.

ASMB vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120Jan 26Apr 26Jul 26Oct 26ASMBS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ASMB analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
EPS revision, 90 days
−184.1%
Analysts raising
2
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
29.6×

Cheaper than 29% of US stocks

Price / sales
6.8×

Cheaper than 16% of US stocks

Price / book
1.5×

Cheaper than 54% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
−31.8%

Higher than 20% of US stocks

Net margin
—
Returns & dividend
Return on equity
−4.6%

Higher than 40% of US stocks

Return on assets
−4.7%

Higher than 33% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Assembly Biosciences, Inc. has a market value of $454.4M and an enterprise value of $142.3M.

  • Revenue in the twelve months to 30 June 2026: $74.8M. The latest quarter grew 38.9% year on year.

  • Net income over the same four quarters: −$42K, a −0.1% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$38.6M.

  • Shares outstanding: 19.9M.

  • Trailing P/E: 29.6×.

  • Assembly Biosciences, Inc. employs 73 people — $1.0M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

ASMB and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ASMBAssembly Biosciences, Inc.$454.4M79
CTMXCytomX Therapeutics, Inc.$438.8M46
PRTAProthena Corp. Plc$442.5M90
CAPRCapricor Therapeutics, Inc.$436.5M13
OCSOculis Holding AG$435.8M30
BLSMBlossomhill Therapeutics, Inc.$444.6M1
DMACDiaMedica Therapeutics, Inc.$444.9M55

Take a look at ASMB’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Assembly Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about ASMB

What is the ASMB stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Assembly Biosciences, Inc. have a median 12-month price target of $50, with estimates ranging from $43 to $62. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ASMB stock a buy right now?

Of the 5 analysts covering Assembly Biosciences, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Assembly Biosciences, Inc. 79 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ASMB?

As at 21 Nov 2026, Assembly Biosciences, Inc. ranks 79 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Quality (96 of 100).

Will ASMB stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +125.3% from the last close, and Ticker Nerd's factor model ranks Assembly Biosciences, Inc. 79 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ASMB stock forecast for 2030?

No analyst covering Assembly Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ASMB are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $43 to $62 over the next 12 months.

How has ASMB stock performed over the past year?

Assembly Biosciences, Inc. returned -39.6% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Assembly Biosciences, Inc. do?

Assembly Biosciences Inc. is a clinical-stage biotechnology company focused on developing small-molecule therapeutics for serious viral and liver diseases. Its current pipeline includes investigational treatments for recurrent genital herpes, hepatitis B virus, hepatitis D virus, and other infectious conditions, with programs designed to target key stages of viral replication and disease progression.

Company

About Assembly Biosciences, Inc.

Assembly Biosciences Inc. is a clinical-stage biotechnology company focused on developing small-molecule therapeutics for serious viral and liver diseases. Its current pipeline includes investigational treatments for recurrent genital herpes, hepatitis B virus, hepatitis D virus, and other infectious conditions, with programs designed to target key stages of viral replication and disease progression. The company also advances research in related areas such as cholestatic liver disease and microbiome-linked disorders through orally delivered therapeutic candidates. Assembly Biosciences Inc. works across discovery, preclinical, and clinical development, positioning itself within the infectious disease and liver disease segments of the biotechnology market. Headquartered in South San Francisco, California, the company concentrates on creating novel treatment approaches intended to address unmet medical needs in virology and liver health.

CEO Mr. Jason A. Okazaki J.D. · 73 employees · United States · https://www.assemblybio.com